

=> d his

FILE 'HOME' ENTERED AT 16:24:25 ON 10 JAN 2005

FILE 'HCAPLUS' ENTERED AT 16:24:32 ON 10 JAN 2005

L1 1 (US20020006606 OR US6811992)/PN
E US1998-85439/AP,PRN

L2 1 US1998-85439P/AP,PRN

L3 1 L1-2

FILE 'REGISTRY' ENTERED AT 16:26:46 ON 10 JAN 2005

FILE 'HCAPLUS' ENTERED AT 16:26:49 ON 10 JAN 2005

L4 TRA L3 1- RN : 10 TERMS

FILE 'REGISTRY' ENTERED AT 16:26:49 ON 10 JAN 2005

L5 10 SEA L4

FILE 'WPDX' ENTERED AT 16:26:53 ON 10 JAN 2005

L6 2 (US20020006606 OR US6811992)/PN

L7 2 US1998-85439P/AP,PRN

L8 2 L6-7

=> b hcap

FILE 'HCAPLUS' ENTERED AT 16:28:00 ON 10 JAN 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Jan 2005 VOL 142 ISS 3

FILE LAST UPDATED: 9 Jan 2005 (20050109/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all 13 ter

L3 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1999:737080 HCAPLUS

DN 131:346549

ED Entered STN: 19 Nov 1999

TI Method to identify JNK- and MLK-kinase inhibiting compounds for prevention of neuron death

IN Liu, Ya Fang

PA USA

SO PCT Int. Appl., 62 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM G01N033-68

ICS G01N033-50; C12Q001-48

CC 1-11 (Pharmacology)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9958982	A1	19991118	WO 1999-US10416	19990512 <--
	W: CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6811992	B1	20041102	US 1998-156367	19980917 <--
	CA 2331680	AA	19991112	CA 1999-2331680	19990512 <--
	EP 1078268	A1	20010228	EP 1999-922972	19990512 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

Search done by Noble Jarrell

JP 2002514767	T2	20020521	JP 2000-548734	19990512 <--
US 2002006606	A1	20020117	US 2001-886964	20010621 <--
US 2002058245	A1	20020516	US 2002-42614	20020109 <--
US 2003148395	A1	20030807	US 2003-360463	20030205 <--
PRAT US 1998-85439D	P	19980514	<--	
US 1998-156367	A1	19980917		
WO 1999-US10416	W	19990512		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
WO 9958982	ICM	G01N033-68	
	ICS	G01N033-50; C12Q001-48	
WO 9958982	ECLA	G01N033/50D2; G01N033/68V2	<--
US 6811992	ECLA	G01N033/50D2; G01N033/68V2	<--
US 2002006606	ECLA	G01N033/50D2; G01N033/68V2	<--
US 2002058245	ECLA	G01N033/50D2; G01N033/68V2	<--
US 2003148395	ECLA	G01N033/50D2; G01N033/68V2	<--
AB		Methods are described for identifying compds. that inhibit JNK and MLK kinase activity as drugs for treating a mammal susceptible to or having a neurol. condition. Methods are also disclosed for preventing neuronal cell death and treating neurol. conditions that involve neuronal cell death, particularly neurodegenerative diseases characterized by glutamine- or kainate-mediated toxicity, e.g. Huntington's disease and Alzheimer's disease.	
ST		JNK MLK kinase inhibitor screening neuroprotectant; Alzheimer drug JNK MLK kinase inhibitor screening; Huntington drug JNK MLK kinase inhibitor screening; neurodegenerative disease JNK MLK kinase inhibitor screening	
IT		Animal cell line (HN33; JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)	
IT		Nervous system (Huntington's chorea; JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)	
IT		Anti-Alzheimer's agents Apoptosis Drug screening Nervous system agents Signal transduction, biological (JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)	
IT		Transcription factors RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (c-jun; JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)	
IT		Amyloid precursor proteins RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study) (carboxyl-terminal fragment; JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)	
IT		Nerve, disease (death; JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)	
IT		Nervous system (degeneration; JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)	
IT		Toxins RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study) (excitotoxins; JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)	
IT		Mutation (mutated protein; JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)	
IT		Proteins, general, biological studies RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study) (mutated; JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)	
IT		Disease models (neurodegeneration; JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)	
IT		Cell death (neuron; JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)	
IT		Cytoprotective agents	

(neuroprotectants; JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)

IT Toxins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(neurotoxins; JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)

IT Proteins, specific or class
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(polyglutamine stretch-expanded huntingtin; JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)

IT Phosphorylation, biological
(protein; JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)

IT 56-86-0, L-Glutamic acid, biological studies 89-00-9, Quinolinic acid 487-79-6, Kainic acid
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)

IT 153190-46-6, MLK3 kinase 155215-87-5, JNK3 kinase 191808-07-8, MLK2 kinase 192230-91-4, SEK1 kinase 250649-03-7, Protein kinase MLK1
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)

IT 26700-71-0, Polyglutamine 69864-43-3, Polyglutamine
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(polyglutamine stretch-expanded huntingtin; JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE
(1) Dickens, M; Science 1997, V277, P693 HCAPLUS
(2) University of Massachusetts; WO 9918193 A 1999 HCAPLUS

=> b reg

FILE 'REGISTRY' ENTERED AT 16:28:08 ON 10 JAN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 JAN 2005 HIGHEST RN 810025-80-0
DICTIONARY FILE UPDATES: 7 JAN 2005 HIGHEST RN 810025-80-0

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d ide 15 tot

L5 ANSWER 1 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN
RN 250649-03-7 REGISTRY
CN Kinase (phosphorylating), protein, MLK1 (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Mixed lineage kinase 1
CN Multiple lineage kinase 1
CN Protein kinase MLK1
MF Unspecified
CI MAN
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL
DT.CA Caplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC

Search done by Noble Jarrell

(Process); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); OCCU (Occurrence);
PROC (Process)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

16 REFERENCES IN FILE CA (1907 TO DATE)
16 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 2 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN
RN 192230-91-4 REGISTRY
CN Kinase (phosphorylating), gene c-jun protein N-terminal kinase/p38 kinase
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN Gene c-jun protein N-terminal kinase kinase 1
CN Gene jkk-1 protein kinase
CN JNK/p38 kinase kinase
CN JNKK1
CN JNKK1 kinase
CN JNKK1 protein kinase
CN Jun N-terminal kinase kinase 1
CN MAP kinase kinase 4
CN MAP2K4
CN MEK4 kinase
CN Mitogen-activated protein kinase hep
CN Mitogen-activated protein kinase kinase 4
CN MKK4 kinase
CN p38 SAPK
CN Protein kinase MEK4
CN Protein kinase MKK4
CN Protein kinase MPK4
CN SAPK/ERK kinase-1
CN SEK1 protein kinase
CN SKK1 protein kinase
CN Stress-activated protein kinase kinase-1
DR 150316-15-7, 179466-44-5, 291756-33-7
MF Unspecified

CI MAN

SR CA

LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA Caplus document type: Conference; Dissertation; Journal; Patent

RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);
OCCU (Occurrence); PROC (Process); PRP (Properties); USES (Uses)

RLD.P Roles for non-specific derivatives from patents: BIOL (Biological
study)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP
(Preparation); PROC (Process); PRP (Properties); USES (Uses)

RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological
study)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

458 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
458 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 3 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN

RN 191808-07-8 REGISTRY

CN Kinase (phosphorylating), protein, MLK2 (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Mixed lineage kinase 2
CN Mixed-lineage protein kinase 2
CN MLK2 kinase
CN MST/MLK2 kinase
CN Multiple lineage kinase 2
CN Protein kinase MLK2
MF Unspecified

CI MAN

SR CA

LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

DT.CA Caplus document type: Dissertation; Journal; Patent

RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);
PREP (Preparation); PROC (Process); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); OCCU (Occurrence);
PROC (Process); PRP (Properties); USES (Uses)

RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological
study); PREP (Preparation); PROC (Process)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

37 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 37 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 4 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 155215-87-5 REGISTRY
 CN Kinase (phosphorylating), gene c-jun protein N-terminal (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN c-Jun amino-terminal kinase
 CN c-Jun amino-terminal protein kinase
 CN c-Jun kinase
 CN c-Jun N-terminal kinase
 CN c-Jun N-terminal protein kinase
 CN Gene c-jun protein kinase
 CN JNK
 CN JNK kinase
 CN JNK protein kinase
 CN Jun kinase
 CN JUN N-terminal kinase
 CN Jun NH2-terminal kinase
 CN Jun-NH2 kinase
 CN Protein kinase JNK
 CN Protein kinase sapk1
 CN Protein kinase SAPK1.gamma.
 CN SAP kinase
 CN SAPK.gamma. kinase
 CN SAPK/JNK kinase
 CN Stress-activated protein kinase
 CN Stress-activated protein kinase-.gamma.
 DR 177893-53-7, 143180-76-1
 MF Unspecified
 CI MAN
 SR CA
 LC STN Files: ADISNEWS, AGRICOLA, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CHEMCATS, CIN, EMBASE, PROMT, TOXCENTER, USPAT2, USPATFULL
 DT.CA Caplus document type: Conference; Dissertation; Journal; Patent; Report
 RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)
 RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
 RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

5330 REFERENCES IN FILE CA (1907 TO DATE)
 60 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 5346 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 5 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 153190-46-6 REGISTRY
 CN Kinase (phosphorylating), gene PTK1 protein (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN Gene PTK1 protein kinase
 CN Gene PTK1 tyrosine kinase
 CN Mixed lineage kinase 3
 CN Mixed lineage kinase MLK3
 CN MLK3 kinase
 CN Multiple lineage kinase 3
 CN Protein kinase MLK3
 CN Protein tyrosine kinase 1
 MF Unspecified
 CI MAN
 SR CA
 LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL
 DT.CA Caplus document type: Dissertation; Journal; Patent

RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study); OCCU (Occurrence); PROC (Process); PRP (Properties)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

78 REFERENCES IN FILE CA (1907 TO DATE)
 78 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 6 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN

RN 69864-43-3 REGISTRY

CN Poly[imino[(1S)-1-(3-amino-3-oxopropyl)-2-oxo-1,2-ethanediyl]] (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Poly[imino[1-(3-amino-3-oxopropyl)-2-oxo-1,2-ethanediyl]], (S)-

OTHER NAMES:

CN Poly(glutamine), SRU

CN Poly(L-glutamine), SRU

CN Poly-L-glutamine

CN Polyglutamine

DR 26603-78-1

MF (C5 H8 N2 O2)n

CI PMS, COM

PCT Polyamide

LC STN Files: ADISNEWS, AGRICOLA, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CEN, CIN, EMBASE, PIRA, PROMT, TOXCENTER, USPAT2, USPATFULL

DT.CA Caplus document type: Conference; Dissertation; Journal; Patent; Preprint


RL.P Roles from patents: BIOL (Biological study); MSC (Miscellaneous); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)

RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent)

RELATED POLYMERS AVAILABLE WITH POLYLINK



305 REFERENCES IN FILE CA (1907 TO DATE)
 25 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 307 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 7 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN

RN 26700-71-0 REGISTRY

CN L-Glutamine, homopolymer (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Glutamine, L-, peptides (8CI)

OTHER NAMES:

CN Glutamine homopolymer

CN Poly-L-glutamine

CN Polyglutamine

FS STEREOSEARCH

MF (C5 H10 N2 O3)x

CI PMS, COM

PCT Polyamide, Polyamide formed

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CEN, CIN, DIOGENES, EMBASE, MEDLINE, PIRA, PROMT, TOXCENTER, USPAT2, USPATFULL

DT.CA Caplus document type: Conference; Dissertation; Journal; Patent;

Preprint

RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)

RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)

RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)


RELATED POLYMERS AVAILABLE WITH POLYLINK

CM 1

CRN 56-85-9

CMF C5 H10 N2 O3

Absolute stereochemistry.



749 REFERENCES IN FILE CA (1907 TO DATE)
 42 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 751 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 8 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN

RN 487-79-6 REGISTRY

CN 3-Pyrrolidineacetic acid, 2-carboxy-4-(1-methylethenyl)-, (2S,3S,4S)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 3-Pyrrolidineacetic acid, 2-carboxy-4-(1-methylethenyl)-, [2S-(2.alpha.,3.beta.,4.beta.)]-

CN 3-Pyrrolidineacetic acid, 2-carboxy-4-isopropenyl- (6CI, 7CI, 8CI)

OTHER NAMES:

CN (-)-.alpha.-Kainic acid

CN (-)-Kainic acid

CN (2S,3S,4S)-2-Carboxy-4-isopropenylpyrrolidine-3-acetic acid

CN .alpha.-Kainic acid

CN Digenic acid

CN Digenin

CN Helminal

CN Kainic acid

CN L-.alpha.-Kainic acid

FS STEREOSEARCH

DR 4071-38-9, 46398-96-3

MF C10 H15 N O4

CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, HODOC*, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PROMT, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
 (*File contains numerically searchable property data)

Other Sources: WHO

DT.CA Caplus document type: Book; Conference; Dissertation; Journal; Patent; Report

RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); MSC (Miscellaneous); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)


RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU

Search done by Noble Jarrell

(Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
 RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

Absolute stereochemistry. Rotation (-).



****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

4629 REFERENCES IN FILE CA (1907 TO DATE)
 45 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 4632 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 26 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L5 ANSWER 9 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN

RN 89-00-9 REGISTRY

CN 2,3-Pyridinedicarboxylic acid (8CI, 9CI) (CA INDEX NAME)

OTHER NAMES:

CN NSC 13127

CN NSC 18836

CN NSC 403247

CN Quinolinic acid

FS 3D CONCORD

MF C7 H5 N O4

CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSChem, DDFU, DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NIOSHTIC, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USPAT2, USPATFULL
 (*File contains numerically searchable property data)

Other Sources: EINECS**, NDSL**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)


DT.CA Caplus document type: Book; Conference; Dissertation; Journal; Patent; Report

RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)

RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)

RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)



****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

1859 REFERENCES IN FILE CA (1907 TO DATE)

Search done by Noble Jarrell

94 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1862 REFERENCES IN FILE CAPLUS (1907 TO DATE)
20 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

LS ANSWER 10 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN

RN 56-86-0 REGISTRY

CN L-Glutamic acid (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Glutamic acid, L- (7CI, 8CI)

OTHER NAMES:

CN (2S)-2-Aminopentanedioic acid

CN (S)-(+)-Glutamic acid

CN (S)-2-Aminopentanedioic acid

CN (S)-Glutamic acid

CN .alpha.-Aminoglutaric acid

CN .alpha.-Glutamic acid

CN 1-Aminopropane-1,3-dicarboxylic acid

CN 2-Aminoglutaric acid

CN 2-Aminopentanedioic acid

CN Aciglut

CN E 620

CN Glusate

CN Glutacid

CN Glutamic acid

CN Glutamicol

CN Glutamindex

CN Glutaminic acid

CN Glutaminol

CN Glutaton

CN L-(+)-Glutamic acid

CN L-.alpha.-Aminoglutaric acid

CN l-Glutaminic acid

CN L-Glutaminic acid

CN NSC 143503

CN Pentanedioic acid, 2-amino-, (S)-

FS STEREOSEARCH

DR 6899-05-4, 10549-13-0, 138-16-9

MF C5 H9 N O4

CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DIPPR*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PIRA, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, TULSA, ULIDAT, USAN, USPAT2, USPATFULL, VETU, VTB

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

DT.CA Caplus document type: Book; Conference; Dissertation; Journal; Patent; Preprint; Report


RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); CMBI (Combinatorial study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)

RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); CMBI (Combinatorial study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)

RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

61152 REFERENCES IN FILE CA (1907 TO DATE)
 2019 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 61210 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> b wpix

FILE WPIX ENTERED AT 16:28:16 ON 10 JAN 2005
 COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE LAST UPDATED: 7 JAN 2005 <20050107/UP>
 MOST RECENT DERWENT UPDATE: 200502 <200502/DW>
 DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
 PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
<http://thomsonderwent.com/coverage/latestupdates/> <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
 GUIDES, PLEASE VISIT:
<http://thomsonderwent.com/support/userguides/> <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT
 DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX
 FIRST VIEW - FILE WPIFV.
 FOR FURTHER DETAILS: <http://www.thomsonderwent.com/dwpifv> <<<

>>> NEW DISPLAY FORMAT HITSTR ADDED ALLOWING DISPLAY OF
 HIT STRUCTURES WITHIN THE BIBLIOGRAPHIC DOCUMENT <<<

>>> SMILES and ISOSMILES strings are no longer available as
 Derwent Chemistry Resource display fields <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501.
 PLEASE CHECK:
<http://thomsonderwent.com/support/dwpieref/reftools/classification/code-revision/>
 FOR DETAILS. <<<

=> d all l8 tot

L8 ANSWER 1 OF 2 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN
 AN 2002-187722 [24] WPIX
 CR 2000-086442 [07]
 DNC C2002-057884
 TI Method of screening a compounds ability to prevent neuronal cell death in
 mammals, affected with neurological conditions such as Huntington's
 disease, Alzheimer's disease.
 DC B03 B04 D16 S03
 IN LIU, Y F
 PA (LIUY-I) LIU Y F
 CYC 1
 PI US 2002006606 A1 20020117 (200224)* 29 C12Q001-00 <--
 ADT US 2002006606 A1 Provisional US 1998-054399 19980514, Div ex US
 1998-156367 19980917, US 2001-886964 20010621
 PRIA US 1998-054399 19980514, US 1998-156367
 19980917; US 2001-886964 20010621
 IC ICM C12Q001-00
 AB US2002006606 A UPAB: 20020610
 NOVELTY - A compound found to have Mixed-lineage kinase (MLK) and/or
 c-Jun N-terminal kinase (JNK) inhibitor activity, is treated with
 mammalian neurons having activated MLK and/or JNK activity. A decrease in
 the number of dead neurons (in the presence of compound), in comparison
 to number of dead neurons (in the compounds absence), indicates the

anti-neuronal apoptosis effect of the compound.

DETAILED DESCRIPTION - A compound is treated with MLK and/or JNK protein and a substrate. The level of JNK and/or MLK activity is measured, if the activity of the JNK and/or MLK is found to decrease in the presence of the compound (when compared to the activity in the absence of the compound), the compound is confirmed to be a JNK and/or MLK inhibitor. This compound is treated with mammalian neurons having activated Mixed-lineage kinase (MLK) and/or c-Jun N-terminal kinase (JNK) activity. The number of dead neurons is determined. A decrease in the number of dead neurons (in the presence of compound), in comparison to the normal number of dead neurons, indicates the ability of the compound to prevent neuronal death.

USE - For treating mammals with neurological diseases such as Huntington's disease or Alzheimer's disease, which involves nerve cell death by glutamate or kainic acid mediated excitotoxicity (claimed).

Dwg. 0/14

FS

CPI EPI

FA

AB; DCN

MC

CPI: B04-F0200E; B04-L04; B11-C08; B11-C08E1; B11-C10; B12-K04A; B12-K04A5; B14-D03; B14-H04; B14-J01; B14-J01A3; B14-J01A4; B14-J01B3; B14-J01B4; B14-J05; B14-J07; B14-N16; B14-N17B; B14-S01; D05-A02B; D05-H09; D05-H14B2

L8 ANSWER 2 OF 2 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2000-086442 [07] WPIX

CR 2002-187722 [21]

DNN N2000-067845 DNC C2000-024051

TI Method of screening a compounds ability to prevent neuronal cell death in mammals, affected with neurological conditions such as Huntington's disease, Alzheimer's disease.

DC B03 B04 D16 S03

IN LIU, Y F

PA (LIUY-I) LIU Y F

CYC 22

PI WO 9958982 A1 19991118 (200007)* EN 62 G01N033-68

RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

W: CA JP US

EP 1078268 A1 20010228 (200113) EN G01N033-68

R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

US 2002006606 A1 20020117 (200224) 29 C12Q001-00 <--

JP 2002514767 W 20020521 (200236) 71 G01N033-50

US 2002058245 A1 20020516 (200237) C12Q001-00

US 2003148395 A1 20030807 (200358) G01N033-53

US 6811992 B1 20041102 (200472) C12Q001-00 <--

ADT WO 9958982 A1 WO 1999-US10416 19990512; EP 1078268 A1 EP 1999-922972

19990512, WO 1999-US10416 19990512; US 2002006606 A1 ~~Provisional US 1998-85439P 19980514~~

~~1998-85439P 19980514~~, Div ex US 1998-156367 19980917, US 2001-886964

20010621; JP 2002514767 W WO 1999-US10416 19990512, JP 2000-548734

19990512; US 2002058245 A1 ~~Provisional US 1998-85439P 19980514~~

Cont of US 1998-156367 19980917, US 2002-42614 20020109; US 2003148395 A1

~~Provisional US 1998-85439P 19980514~~, Cont of US 1998-156367

19980917, US 2003-360463 20030205; US 6811992 B1 ~~Provisional US 1998-85439P 19980514~~

~~1998-85439P 19980514~~, US 1998-156367 19980917

FDT EP 1078268 A1 Based on WO 9958982; JP 2002514767 W Based on WO 9958982

PRAI US 1998-156367 19980917; ~~US 1998-85439P 19980514~~

~~19980514~~; US 2001-886964 20010621; US 2002-42614

20020109; US 2003-360463 20030205

IC ICM C12Q001-00; G01N033-50; G01N033-53; G01N033-68

ICS C12P021-06; C12Q001-48; C12Q001-68; G01N033-15; G01N033-567

AB WO 9958982 A UPAB: 20020618

NOVELTY - A compound found to have Mixed-lineage kinase (MLK) and/or c-Jun N-terminal kinase (JNK) inhibitor activity, is treated with mammalian neurons having activated MLK and/or JNK activity. A decrease in the number of dead neurons (in the presence of compound), in comparison to number of dead neurons (in the compounds absence), indicates the anti-neuronal apoptosis effect of the compound.

DETAILED DESCRIPTION - A compound is treated with MLK and/or JNK protein and a substrate. The level of JNK and/or MLK activity is measured, if the activity of the JNK and/or MLK is found to decrease in the presence of the compound (when compared to the activity in the absence of the compound), the compound is confirmed to be a JNK and/or MLK inhibitor. This compound is treated with mammalian neurons having activated Mixed-lineage kinase (MLK) and/or c-Jun N-terminal kinase (JNK) activity. The number of dead neurons is determined. A decrease in the number of dead neurons (in the presence of compound), in comparison to the normal number of dead neurons, indicates the ability of the compound

to prevent neuronal death.

USE - For treating mammals with neurological diseases such as Huntington's disease or Alzheimer's disease, which involves nerve cell death by glutamate or kainic acid mediated excitotoxicity (claimed).
Dwg.0/14

FS CPI EPI

FA AB; DCN

MC CPI: B04-F02; B04-N02; B11-C08E2; B12-K04A; D05-H09
EPI: S03-E14H

=> b home

FILE 'HOME' ENTERED AT 16:28:31 ON 10 JAN 2005

=>